Economic Evaluation of Drug Resistance Genotyping for the Adaptation of Treatment in HIV-Infected Patients in the VIRADAPT Study
- 1 July 2000
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 24 (3) , 227-231
- https://doi.org/10.1097/00042560-200007010-00005
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- How Good Are US Studies of HIV Costs of Care?Medical Care, 1999
- Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trialThe Lancet, 1999
- The Care of HIV-Infected Adults in the United StatesNew England Journal of Medicine, 1998
- Analysis and interpretation of cost data in randomised controlled trials: review of published studiesBMJ, 1998
- Dossier médical informatisé pour les patients atteints d'infection par le VIH (ADDIS): l'expérience du Service des Maladies infectieuses du CHU de NiceMedecine Et Maladies Infectieuses, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and MedicineJAMA, 1996
- Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in PlasmaScience, 1996